In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Med BioGene closes first tranche of financing

Executive Summary

Med BioGene (diagnostic and prognostic tests for cancer and cardiovascular disease) has closed the first tranche of a public offering. It sold 10.7mm units at $Cdn0.15 each, grossing $Cdn1.6mm ($1.5mm). Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant is exercisable into one common share at $Cdn0.20 for two years. PI Financial was the placement agent.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies